Browsing Tag
Glaukos Corporation
1 post
Glaukos (NYSE: GKOS) targets $1bn in sales. Can Epioxa offset iDose risk?
Glaukos shares surged in after-hours trading after the company raised its 2026 revenue forecast and introduced a US$1 billion sales target for 2027. But the ambitious outlook depends on a successful Epioxa rollout and continued demand for iDose TR, whose Medicare coverage remains under review.